Femasys Inc (FEMY) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam

ATLANTA, June 27, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company...

Form 8-K - Current report

Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe

ATLANTA, June 20, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company...

Form DEF 14A - Other definitive proxy statements

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative

ATLANTA, May 17, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused...

Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council

ATLANTA, May 16, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update

-- Recruitment of the commercial team for our infertility portfolio and the pivotal trial of FemBloc® for...

Femasys Expands Commercial Management Team with Addition of Experienced New Hires

ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (Nasdaq: FEMY), a leading biomedical company focused...

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives

ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused...